Human Epidermal Growth Factor-2 Receptor [HER2] Status in Patients Aged 70 years or more with Operable Early Breast Cancer — Multicentre Based Study with Review of 150 Cases
, 2, 3, 4, 5, 3, 6
Abstract
Background: Breast cancer is the most common invasive cancer in females but often has more favourable
tumour biology in the older age group. More than 30% of those diagnosed with breast cancer worldwide are
aged ≥ 65. Some report this percentage to be even higher, reaching up to more than 50% in developed
countries that have a longer overall life expectancy. Within this group, hormone receptor-positive and human epidermal growth factor-2 (HER-2) negative are the most favourable tumour biological patterns. In contrast, the triple-negative breast cancer group has the worst prognosis. Invasive breast cancers in younger age groups have a more poorly differentiated histological grade, more hormone receptor-negative status, a remarkable extent of lympho-vascular invasion and a greater expression/amplification of HER-2 than older age groups. HER-2 receptor is amplified and over-expressed in about 20–30% of invasive
breast cancers within all age groups. To analyse the status of HER-2 receptors early invasive breast cancer in relation to the histological subtype in the older age group.
Methods: The study group includes 150 patients with early breast cancer . The patho-morphological data and immune-histochemistry results of invasive cancer have been analysed, this included histology subtype,
grade, oestrogen/progesterone receptor status as well as HER-2 expression.
Results: HER-2 expression was only seen in 17% of cases, it was seen mainly in Grade 3 cancers (9%), followed by Grade 2 (6%), with Grade 1 cancer accounting for only 1% of the study group.
Conclusions: Patients with breast cancer aged ≥ 70 are seen to have less aggressive biology and expression
of HER-2 receptors.
Keywords: breast cancerHER-2 receptortrastuzumab
References
- DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64(1): 52–62.
- National Cancer Institute: Breast cancer risk in American women. http://www.cancer.gov/cancertopics/types/breast/risk-fact-sheet (19.11.2017).
- Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol. 2001; 12 Suppl 1: S35–S41.
- Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001; 12 Suppl 1: S3–S8.
- Orucevic A, Curzon M, Curzon C, et al. Breast Cancer in Elderly Caucasian Women-An Institution-Based Study of Correlation between Breast Cancer Prognostic Markers, TNM Stage, and Overall Survival. Cancers (Basel). 2015; 7(3): 1472–1483.
- Aapro M, Wildiers H. Triple-negative breast cancer in the older population. Ann Oncol. 2012; 23 Suppl 6: vi52–vi55.
- Daidone MG, Coradini D, Martelli G, et al. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol. 2003; 45(3): 313–325.
- Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000; 92(7): 550–556.
- Molino A, Giovannini M, Auriemma A, et al. Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer. Crit Rev Oncol Hematol. 2006; 59(3): 226–233.
- Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984; 2(10): 1102–1109.
- Durbecq V, Ameye L, Veys I, et al. A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics. Crit Rev Oncol Hematol. 2008; 67(1): 80–92.
- Freedman RA, Muss HB. Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient. J Geriatr Oncol. 2014; 5(1): 2–7.
- Lodi M, Scheer L, Reix N, et al. Breast cancer in elderly women and altered clinico-pathological characteristics: a systematic review. Breast Cancer Res Treat. 2017; 166(3): 657–668.
- Slamon D, Eiermann W, Robert N, et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14): 1273–1283.
- Romond E, Perez E, Bryant J, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med. 2005; 353(16): 1673–1684.
- Leyland-Jones B, Arnold A, Gelmon K, et al. Pharmacologic insights into the future of trastuzumab. Ann Oncol. 2001; 12 Suppl 1: S43–S47.
- Baselga J. Phase I and II clinical trials of trastuzumab. Annals of Oncology. 2001; 12(suppl 1): S49–S55.
- Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014; 32(33): 3744–3752.
- Muss HB. Adjuvant chemotherapy in older women with breast cancer: who and what? J Clin Oncol. 2014; 32(19): 1996–2000.
- Dall P, Lenzen G, Göhler T, et al. Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany. J Geriatr Oncol. 2015; 6(6): 462–469.
- Denegri A, Moccetti T, Moccetti M, et al. Cardiac toxicity of trastuzumab in elderly patients with breast cancer. J Geriatr Cardiol. 2016; 13(4): 355–363.
- Sun J, Chia S. Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly. Br J Cancer. 2017; 116(1): 4–9.